Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2021
2019
Profitability Metrics
Gross Margin
72.30%
Operating Margin
14.45%
Net Margin
11.38%
Efficiency Metrics
Revenue per Expense Ratio
1.17
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
15.33%
Income Tax Rate
21.12%
EPS
3.3700000000
Balance Sheet Analysis
Current Ratio
0.43
Cash Ratio
1.35
Working Capital
$-9.10B
Debt to Equity
0.41
Debt to Assets
9.29%
Equity Ratio
22.65%
Cash Flow Analysis
Operating Cash Flow Ratio
24.57%
Free Cash Flow Ratio
24.13%
CapEx to Revenue
0.44%
Dividends Paid
$501.46M
Stock Buybacks
$537.16M
Total Shareholder Returns
$1.04B
Cash Position Change
-5.94%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 117.92%
Detailed Growth Metrics
Core Performance
Revenue
8.25%
Net Income
0.02%
EPS
1.20%
Operating Income
-4.97%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
-100.00%
Operating Cash Flow
14.04%
Free Cash Flow
14.32%
Balance Sheet Health
Assets
-2.87%
Debt
-0.01%
Book Value per Share
12.79%
Inventory
100.00%
Shareholder Returns
Dividends per Share
117.92%
Shares Outstanding
-2.16%
Long Term Trends
3Y Revenue/Share
55.55%
5Y Revenue/Share
66.00%
3Y Dividend/Share
518.24%
5Y Dividend/Share
107.54%